Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CytoDyn Inc CYDY

Healthcare Biotechnology
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.


OTCQB:CYDY - Post by User

CytoDyn Inc
Bullboard Posts
User Avatar Image
(1)
•••
Post by sunny3999on May 12, 2020 5:39am
119 Views
Post# 31015386

Cytodyn's and Leronlimab is trending up nearly worldwide

Cytodyn's and Leronlimab is trending up nearly worldwide
Cytodyn search (last day by countries):
https://trends.google.de/trends/explore?date=now%201-d&q=%2Fg%2F1dtt2r0k
 
Leronlimab search (last day by countries):
https://trends.google.de/trends/explore?date=now%201-d&q=Leronlimab
 
search for monoclonal antibody +650% (worldwide):
https://trends.google.de/trends/explore?q=%2Fm%2F01tr0r&date=now%201-d
 
I would say it looks excellent so far!
 
GLTA
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities